Rituximab chimeric anti-CD20 monoclonal antibody therapy for adults with chronic idiopathic thrombocytopaenic purpura
STASI R, PAGANO A, STIPA E, AMADORI S. Rituximab chimeric anti-CD20 monoclonal antibody therapy for adults with chronic idiopathic thrombocytopaenic purpura. Blood 2001;98:952-957.
Anti-CD20 therapy for chronic lymphocytic leukaemia-associated autoimmune diseases
ZAJA F, VIANELLI N, SPEROTTO A, PATRIARCA F, TANI M, MARIN L, TIRIBELLI A, CABDONI A, BACCARANI M, FANIN R. Anti-CD20 therapy for chronic lymphocytic leukaemia-associated autoimmune diseases. Leukaemia Lymphoma 2003;44:1951-1955.
Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy
CORBELLING M, BESTETTI G, SCALAMOGNA C et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 2001;98:3473-3475.
Systemic Castleman's disease in association with Evan's syndrome and vitiligo
MARSH JH, COLBOURN DS, DONOVAN V, STASZEWSKI H. Systemic Castleman's disease in association with Evan's syndrome and vitiligo. Med Paediatr Oncol 1990;18:169-172.
Rituximab for immune cytopaenia in adults: Idiopathic thrombocytopaenia purpura, autoimmune haemolytic anaemia, and Evan's syndrome
SHANAFELT TD, MADUENE HL, WOLF RC, TEFFERI A. Rituximab for immune cytopaenia in adults: idiopathic thrombocytopaenia purpura, autoimmune haemolytic anaemia, and Evan's syndrome. Mayo Clinic Proc 2003;78:1340-1346.
Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukaemia and Evan's syndrome
SEIPELT G, BOHME A, KOSCHNEIDER S, HOELZER D. Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukaemia and Evan's syndrome. Ann Hematol. 2001;80:170-173.